CG Oncology (CGON) Interest Expenses (2023 - 2026)

CG Oncology's Interest Expenses history runs 4 years deep, the most recent figure standing at $382.9 million for Q1 2026.

• Quarterly Interest Expenses rose 338.54% year-over-year to $382.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $382.9 million (up 338.54% YoY) and the FY2025 annual result came in at $198.5 million, up 83.57% from the prior year.
• Interest Expenses was $382.9 million for Q1 2026 at CG Oncology, up from $205000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $382.9 million in Q1 2026 and bottomed at $45000.0 in Q2 2023.
• A 4-year average of $109.1 million and a median of $97.0 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2024 — Interest Expenses jumped 339975.56% — and 2025, when it slumped 62.23%.
• CG Oncology's Interest Expenses stood at $59000.0 in 2023, then grew by 1.69% to $60000.0 in 2024, then surged by 241.67% to $205000.0 in 2025, then soared by 186676.59% to $382.9 million in 2026.
• Business Quant data shows CGON's Interest Expenses at $382.9 million in Q1 2026, $205000.0 in Q4 2025, and $190.7 million in Q3 2025.